Tong Leslie M, Yoon Seo Yeon, Andrews-Zwilling Yaisa, Yang Alyssa, Lin Victoria, Lei Hanci, Huang Yadong
Gladstone Institute of Neurological Disease, San Francisco, California 94158, and Biomedical Sciences Graduate Program, and.
Gladstone Institute of Neurological Disease, San Francisco, California 94158, and.
J Neurosci. 2016 Feb 17;36(7):2316-22. doi: 10.1523/JNEUROSCI.3815-15.2016.
Apolipoprotein E4 (apoE4) is the major genetic risk factor for Alzheimer's disease (AD). However, the underlying mechanisms are still poorly understood. We previously reported that female apoE4 knock-in (KI) mice had an age-dependent decline in hilar GABAergic interneurons that correlated with the extent of learning and memory deficits, as determined by Morris water maze (MWM), in aged mice. Enhancing GABA signaling by treating aged apoE4-KI mice with the GABAA receptor potentiator pentobarbital (PB) for 4 weeks before and during MWM rescued the learning and memory deficits. Here, we report that withdrawal of PB treatment for 2 weeks before MWM abolished the rescue in aged apoE4-KI mice, suggesting the importance of continuously enhancing GABA signaling in the rescue. However, treating apoE4-KI mice during middle adulthood (9-11 months of age) with PB for 6 weeks prevented age-dependent hilar GABAergic interneuron decline and learning and memory deficits, when examined at 16 month of age. These data imply that increasing inhibitory tone after substantial GABAergic interneuron loss may be an effective symptomatic, but not a disease-modifying, treatment for AD related to apoE4, whereas a similar intervention before substantial interneuron loss could be a disease-modifying therapeutic.
We previously reported that female apoE4-KI mice had an age-dependent decline in hilar GABAergic interneurons that correlated with the extent of cognitive deficits in aged mice. The current study demonstrates that enhancing GABA signaling by treating aged apoE4-KI mice with a GABAA receptor potentiator pentobarbital (PB) before and during behavioral tests rescued the cognitive deficits; but withdrawal of PB treatment for 2 weeks before the tests abolished the rescue, suggesting the importance of continuously enhancing GABA signaling. However, treating apoE4-KI mice during middle adulthood with PB for a short period of time prevented age-dependent hilar GABAergic interneuron decline and cognitive deficits late in life, suggesting early intervention by enhancing GABA signaling as a potential strategy to prevent AD related to apoE4.
载脂蛋白E4(apoE4)是阿尔茨海默病(AD)的主要遗传风险因素。然而,其潜在机制仍知之甚少。我们之前报道,雌性apoE4基因敲入(KI)小鼠海马门区GABA能中间神经元数量随年龄下降,且与老年小鼠的学习和记忆缺陷程度相关,这一缺陷程度由莫里斯水迷宫(MWM)测定。在MWM测试前及测试期间,用GABAA受体增强剂戊巴比妥(PB)处理老年apoE4-KI小鼠4周,增强GABA信号传导,挽救了其学习和记忆缺陷。在此,我们报告,在MWM测试前2周停止PB处理后,老年apoE4-KI小鼠的这种挽救作用消失,这表明持续增强GABA信号传导在挽救过程中的重要性。然而,在成年中期(9至11月龄)用PB处理apoE4-KI小鼠6周,在16月龄时检查发现,可预防海马门区GABA能中间神经元数量随年龄下降以及学习和记忆缺陷。这些数据表明,在大量GABA能中间神经元丧失后增加抑制性张力可能是一种有效的对症治疗方法,但不是针对与apoE4相关的AD的疾病修饰治疗方法,而在大量中间神经元丧失之前进行类似干预可能是一种疾病修饰疗法。
我们之前报道,雌性apoE4-KI小鼠海马门区GABA能中间神经元数量随年龄下降,且与老年小鼠认知缺陷程度相关。当前研究表明,在行为测试前及测试期间,用GABAA受体增强剂戊巴比妥(PB)处理老年apoE4-KI小鼠,增强GABA信号传导,挽救了认知缺陷;但在测试前2周停止PB处理后,这种挽救作用消失,这表明持续增强GABA信号传导的重要性。然而,在成年中期用PB短期处理apoE4-KI小鼠,可预防海马门区GABA能中间神经元数量随年龄下降以及晚年认知缺陷,这表明通过增强GABA信号传导进行早期干预是预防与apoE4相关的AD的潜在策略。